Table 4 Literature review of SBRT for cholangiocarcinoma
Reference | Year | Patients (n) | Total Dose (Gy) | Fractions | 12-month LC (%) | Median OS (months) | Comments |
|---|---|---|---|---|---|---|---|
Herfarth et al. [13] | 2001 | 3 | 14 - 26 | 1 | 71 | NR | Target volume covered by 80% isodose |
Tse et al. [16] | 2008 | 10 | 32.5 | 6 | 65 | 15 | Hypofractionated stereotactic radiotherapy |
Goodman et al. [12] | 2010 | 5 | 18 - 30 | 1 | 77 | 29 | Single-fraction dose escalation study |
Kopek et al. [14] | 2010 | 27 | 45 | 3 | NR | 11 | 22% rate of serious GI injury |
Polistina et al. [15] | 2011 | 10 | 30 | 3 | NR | 36 | All patients received concurrent gemcitabine |
Current Study | 2012 | 10 | 55 | 5 | 100 | 14 | Includes both recurrent and metastatic lesions |